76 Results

People

  1. Yu
    Yu
  2. Riely
    Riely
  3. Kris
    Kris
  4. Ladanyi
    Ladanyi
  5. Arcila
    Arcila
  6. Drilon
    Drilon
  7. Rudin
    Rudin
  8. Jones
    Jones
  9. Offin
    Offin
  10. Schoenfeld
    Schoenfeld

Groups

  1. Department of Medicine (58)
  2. Solid Tumor Oncology Division (56)
  3. Thoracic Oncology (53)
  4. GSK Faculty (15)
  5. Department of Pathology and Laboratory Medicine (14)
  6. Human Oncology and Pathogenesis Program (13)
  7. Sloan Kettering Institute Postdocs (13)
  8. Graduate Medical Education (11)
  9. Weinberg Fellows (11)
  10. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (10)
  1. "osimertinib"
Formats
  1. Journal Article (43)
  2. Editorial (10)
  3. Meeting Abstract (9)
  4. Review (8)
  5. Guidelines (3)
  6. Conference Paper (2)
  7. Correspondence (1)
Groups
  1. Department of Medicine (58)
  2. Solid Tumor Oncology Division (56)
  3. Thoracic Oncology (53)
  4. GSK Faculty (15)
  5. Department of Pathology and Laboratory Medicine (14)
  6. Human Oncology and Pathogenesis Program (13)

More Groups

People
  1. Helena Yu (37)
  2. Gregory Riely (15)
  3. Mark Kris (11)
  4. Marc Ladanyi (10)
  5. Bob Li (7)
  6. Maria Arcila (7)

More People

Years
  1. 2025 (6)
  2. 2024 (17)
  3. 2023 (8)
  4. 2022 (10)
  5. 2021 (10)
  6. 2020 (4)

More Years

Publications
  1. Journal of Thoracic Oncology (14)
  2. Clinical Cancer Research (9)
  3. Annals of Oncology (8)
  4. Cancer Discovery (7)
  5. Journal of Clinical Oncology (5)
  6. Journal of Thoracic and Cardiovascular Surgery (4)

More Publications

Publishers
  1. Elsevier Inc. (17)
  2. American Association for Cancer Research (16)
  3. Oxford University Press (9)
  4. American Society of Clinical Oncology (7)
  5. Elsevier Science, Inc. (4)
  6. Mosby Elsevier (4)

More Publishers

Results (76)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Osimertinib-chemotherapy synergy in EGFR-mutant NSCLC: Advancing central nervous system control amidst toxicity considerations
    Editorial

    Kumar, R.; Miao, E.; Pike, L. R. G.
    Translational Cancer Research (2025)

    Fulltext@MSK | Save
  • A podcast discussion on the intracranial efficacy of antibody–Drug conjugates in patients with EGFR-mutated NSCLC with brain metastases
    Editorial

    Johnson, M. L.; Lin, J. J.; Boire, A.; Khandekar, M. J.; Yu, H. A.
    Oncology and Therapy (2025)

    Fulltext@MSK | Save
  • Determinants of successful minimally invasive surgery for resectable non–small cell lung cancer after neoadjuvant therapy
    Conference Paper

    Chu, N. Q.; Tan, K. S.; Dycoco, J.; Adusumilli, P. S.; Bains, M. S.; Bott, M. J.; Downey, R. J.; Gray, K. D.; Huang, J.; Isbell, J. M.; more...
    Mosby Elsevier (2025)

    Fulltext@MSK | Save
  • Financial challenges of being on long-term, high-cost medications
    Review

    Elshiekh, C.; Rudà, R.; Scheffer Cliff, E. R.; Gany, F.; Budhu, J. A.
    Neuro-Oncology Practice (2025)

    Fulltext@MSK | Save
  • Synergistic effect of HAD-B1 and osimertinib against gefitinib resistant HCC827 non-small cell lung cancer cells
    Journal Article

    Ko, E. J.; Kwag, E. B.; Park, J. H.; Cho, S. H.; Park, S. J.; Jung, M. K.; Kang, I. C.; Yoo, H. S.
    Integrative Cancer Therapies (2025)

    Fulltext@MSK | Save
  • Overview of molecular prognostication for common solid tumor histologies – What the surgeon should know
    Journal Article

    Goodwin, C. R.; De la Garza Ramos, R.; Bettegowda, C.; Barzilai, O.; Shreyaskumar, P.; Fehlings, M. G.; Laufer, I.; Sahgal, A.; Rhines, L. D.; Reynolds, J. J.; more...
    Global Spine Journal (2025)

    Fulltext@MSK | Save
  • Overall survival after treatment with first-line osimertinib for EGFR-mutant advanced NSCLC in the US
    Meeting Abstract

    Sabari, J. K.; Yu, H. A.; Mahadevia, P.; Liu, Y.; Demirdjian, L.; Sultan, A. A.; Chen, Y. H.; Wang, X.; Passaro, A.
    Journal of Thoracic Oncology (2024)

    Fulltext@MSK | Save
  • Phase III KEYNOTE-789 study of pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor-resistant, EGFR-mutant, metastatic nonsquamous non-small cell lung cancer
    Journal Article

    Yang, J. C. H.; Lee, D. H.; Lee, J. S.; Fan, Y.; de Marinis, F.; Iwama, E.; Inoue, T.; Rodríguez-Cid, J.; Zhang, L.; Yang, C. T.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Phase 2 trial of regorafenib in recurrent/metastatic adenoid cystic carcinoma
    Journal Article

    Desilets, A.; Vos, J. L.; Katabi, N.; Kuo, F.; Nadeem, Z.; Linxweiler, M.; Ostrovnaya, I.; Baxi, S.; Dunn, L. A.; Sherman, E. J.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • A phase 1 first-in-human study of the MCL-1 inhibitor AZD5991 in patients with relapsed/refractory hematologic malignancies
    Journal Article

    Desai, P.; Lonial, S.; Cashen, A.; Kamdar, M.; Flinn, I.; O'Brien, S.; Garcia, J. S.; Korde, N.; Moslehi, J.; Wey, M.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save